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for regulating metabolism in response to energy supply and demand. Drugs that activate
AMPK may be useful in the treatment of metabolic diseases including type 2 diabetes.
We have determined the crystal structure of AMPK in complex with its activator
5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid (C2), revealing two C2-binding sites in
the g-subunit distinct from nucleotide sites. C2 acts synergistically with the drug A769662 to
activate AMPK a1-containing complexes independent of upstream kinases. Our results show
that dual drug therapies could be effective AMPK-targeting strategies to treat metabolic
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A
MP-activated protein kinase (AMPK) is a metabolic
stress-sensing kinase responsible for regulating metabo-
lism in response to energy supply and demand. During
metabolic stress the cellular AMP/ATP ratio increases leading to
activation of AMPK, which in turn switches off energy-
consuming anabolic pathways and switches on catabolic path-
ways to restore ATP levels. The AMPK abg heterotrimer
comprises a catalytic a-subunit associated with b and g regulatory
subunits (Fig. 1a). Adenine nucleotides (ATP, ADP and AMP)
bind interchangeably to the g subunit where three of the four
cystathionine b-synthase (CBS) tandem-repeat sequences provide
nucleotide-binding sites1. Allosteric activation of AMPK by AMP
appears to involve all three sites but site 3 may be the most
important2,3. AMP binding initiates AMPK signalling by
promoting phosphorylation of AMPK on a-Thr172 by
upstream kinases LKB1 and Ca2þ /calmodulin-dependent
protein kinase 2 (CaMKK2). Once phosphorylated on a-Thr172
AMPK is further activated by AMP, and AMP sustains AMPK
signalling by inhibiting dephosphorylation of a-pThr172 (ref. 4).
AMP stimulation of aThr172 phosphorylation is dependent
on N-terminal myristoylation of the b-subunit, since we
demonstrated that AMP stimulation by both upstream kinases
is lost following b-G2A mutation2. ATP on the other hand
opposes allosteric activation by AMP as well as promoting the
dephosphorylation of a-Thr172 (ref. 5). The a-regulatory
subunit-interacting motif 2 (aRIM2; Fig. 1a)6 is required for
sensing the adenine nucleotide bound state of the g-subunit and
transducing this signal to the a-catalytic domain, resulting
in either stimulation (AMP) or inhibition (ATP) of AMPK
activity1,6–8.
There has been keen interest in developing AMPK-activating
drugs for potential therapeutic use in treating metabolic diseases
including type 2 diabetes, obesity and cardiovascular disease.
A number of small-molecule activators have been identiﬁed9 and
two of these, A769662 (Abbott Laboratories) and 991 (Merck
Sharp and Dohme Corporation and Metabasis Therapeutics),
were shown in milestone structures to bind to a site formed
between the small lobe of the a-subunit kinase domain and the
b-subunit carbohydrate-binding module (CBM)8,10 termed the
allosteric drug and metabolite-binding site (ADaM)11. Salicylate,
the active metabolite of aspirin, is also thought to bind to this
site12. ADaM site stabilization is enhanced by phosphorylation of
the b-subunit residue Ser108 (refs 13,14). We have shown that the
need for b-pSer108 can be bypassed and that dephosphorylated
AMPK (or dephosphorylation mimic a1-T172Ab1-S108Ag1
mutant) can be activated synergistically by A769662 and AMP
whereas there is negligible activity with either activator alone13.
Another potent small-molecule allosteric activator of
AMPK, 5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid
(compound 2, C2, Metabasis Therapeutics), was identiﬁed by
screening an AMP mimetic library15. It is thought that C2
activates both AMPK a1 and a2 isoforms in cell-free assays by
binding to the g-subunit. Although C2 is impermeable to cells, its
corresponding di-iso-propyl phosphoester prodrug (compound
13, C13) preferentially stimulates AMPK a1 in mammalian
cells16. AMP and C2 likely share a common AMPK-activating
mechanism as their allosteric effects are not additive, and
sensitivity to both is lost in the g2-R531G AMP-insensitive
mutant16. The purpose of our study was to identify the
C2-binding site(s) on AMPK and investigate the relationship
between activation of AMPK by A769662 and C2.
We have determined the crystal structure of the C2: AMPK
complex, revealing two C2-binding sites in the g-subunit distinct
from nucleotide sites. C2 acts synergistically with the drug
A769662 to activate AMPK a1-containing complexes indepen-
dent of upstream kinases. Our results raise the possibility that
dual drug therapies could be effective AMPK-targeting strategies
to treat metabolic diseases.
Results
Allosteric activation of AMPK. We found that C2 activates both
AMPK g1 and g2 complexes (a1b1g1 and a1b2g1; a1b1g2 and
a1b2g2) to a similar degree as AMP, whereas neither C2 nor
AMP-activated g3-containing complexes (a1b1g3 and a1b2g3)
(Fig. 1b). Lack of AMP activation of g3-containing complexes has
also been reported recently17 but not in all studies18,19.
Since ATP concentration was previously shown to alter AMP
dependence5, we investigated C2 activation of AMPK a1 at
low (20 mM) and physiological (2mM) ATP concentrations.
Comparison of dose–response curves revealed that the
half-maximal concentrations for C2 activation were similar at
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Figure 1 | Allosteric activation of AMPK by C2. (a) Schematic
representation of the three AMPK subunits: the catalytic a-subunit, and the
regulatory b and g-subunits. (b) C2 activation of AMPK a1 complexes.
Activities of COS7 cell-expressed AMPK (complexes as indicated) were
assayed in the absence or presence of C2 (0.1 mM) or AMP (100mM).
Results from triplicate experiments are presented as mean AMPK activity
(fold change relative to basal±s.e.m.), with statistical tests conducted
using one-way ANOVA. *Po0.05 indicates signiﬁcant increase in activity
compared to untreated control. Effect of ATP concentration on C2
activation of AMPK a1. C2 dose–response (0–5mM) at (c) low (20 mM)
ATP and (d) near-physiological (2mM) ATP. Results from six independent
experiments are plotted as AMPK activity (fold change±s.e.m.) versus
[C2] (nM). The values for EC50, fold stimulation and Hill coefﬁcients
were calculated based on ﬁtting the data to the equation:
Activity¼Basalþ (((Fold stimulation Basal) Basal [C2]h)/
((EC50)
hþ [C2]h)). AID, auto-inhibitory domain; CBM, carbohydrate-
binding module; CBS, cystathionine b-synthase motif; KD, kinase domain;
RIM, regulatory subunit-interacting motif; SD, scaffold domain.
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both low and high ATP (52.3±7.9 and 50.3±4.4 nM for 20 mM
and 2mM ATP, respectively; Fig. 1c,d), implying that C2 and
ATP binding is non-competitive. In contrast, previous studies
have shown that the concentration of AMP required for half-
maximal activation increases with higher concentrations of ATP,
which is consistent with AMP/ATP competition at the g-subunit
allosteric sites5. We also observed that C2 activation becomes
strongly co-operative at high ATP, as shown by a shift in the Hill
coefﬁcient from 1.4±0.3 (20 mM ATP) to 2.3±0.4 (2mM ATP)
(Fig. 1c,d). In contrast, AMP does not exhibit co-operative
binding at high ATP concentrations (Hill coefﬁcient 1.0±0.2;
Supplementary Fig. 1 and Supplementary Table 1). We are
uncertain of the structural basis for the effect of ATP on C2
co-operative binding as well as the kinetic basis for ATP not
inﬂuencing AMP activation in a co-operative manner. The
g-subunit resembles a classic multimeric-enzyme with its 4 CBS
tandem repeats. One interpretation is that ATP binding to the
g-subunit inﬂuences C2 co-operativity but we have been unable
to obtain crystals with both C2 and ATP bound to the g-subunit
thus far. In the event ATP cannot bind to g in the presence of C2
we cannot formally eliminate the possibility that ATP binding at
the kinase active site (a-subunit) rather than the g-subunit may
induce C2 co-operative binding.
Synergistic activation of AMPK. We examined whether C2, like
AMP, can synergize with A769662 to activate dephosphorylated
AMPK (Supplementary Fig. 2a). Furthermore, we explored
whether this synergistic activation is also present in the AMPK
a2 isoform. Modest allosteric activations were observed with
l-phosphatase pre-treated AMPK a1 or a2 complexes individu-
ally incubated with AMP or C2 or A769662 (Fig. 2a). We attri-
bute the larger A769662 response using AMPK a1 to residual
b1-Ser108 phosphorylation persisting after l-phosphatase treat-
ment (Supplementary Fig. 2a). Synergistic activation occurred
when the l-phosphatase-treated AMPK a1 (basal activity
E0.6 nmolmin 1mg 1) was co-incubated with combinations
of AMP/A769662 (E671 nmolmin 1mg 1 orE1100-fold) and
C2/A769662 (E636 nmolmin 1mg 1 orE1040-fold), but not
with CaMKK2-treated AMPK a1 (Fig. 2a,b; Table 1). It should
be noted the maximum activity observed in C2-stimulated,
CaMKK2-treated AMPK a1 is Ethreefold higher than the
maximum activity observed with the l-phosphatase-treated
AMPK a1 co-incubated with C2/A769662. Moreover, the syner-
gistic activation was speciﬁc to AMPK a1, as the l-phosphatase-
treated AMPK a2 (basal activity E1.2 nmolmin 1mg 1)
co-incubated with AMP/A769662 or C2/A769662 was
relatively insensitive to dual ligand activation (AMP/A769662
activation E7.2 nmolmin 1mg 1 or E6.1-fold; C2/A769662
activation E1.3 nmolmin 1mg 1 or E1.2-fold; Fig. 2a;
Table 1). Similarly to CaMKK2-treated AMPK a1, the CaMKK2-
treated AMPK a2 did not exhibit dual synergistic activation by
both AMP/A769662 and C2/A769662 (Fig. 2b).
Novel C2-binding site in the c-subunit. To gain further insight
into the mechanism of C2-mediated AMPK activation we solved
the X-ray crystal structure of full-length a2b1g1 isoform co-
crystallized with C2 and AMP to 2.99 Å resolution (Table 2). The
structure revealed two molecules of C2, bound within the solvent-
accessible core of the g-subunit. The phosphate groups of both C2
molecules overlap the phosphate binding sites of AMP in sites 1
and 4, while the 5-(5-hydroxyl-isoxazol-3-yl)-furan moieties
occupy novel binding sites independent from the AMP-binding
sites (Fig. 3a–c; Supplementary Fig. 3a). The asymmetric unit
contained two AMPK heterotrimers. One heterotrimer contained
AMP bound at each of CBS sites 3 and 4 (Fig. 3a, white) whereas
the other heterotrimer was devoid of AMP and fortuitously
contained two molecules of C2 instead (Fig. 3a–c). The two
distinct liganded complexes allowed us to comprehensively probe
the differences between AMP and C2 binding to AMPK.
Our AMP-bound heterotrimer closely resembles the previously
published AMP-bound a2b1g1 structure (PDB 4CFE)8. The two
molecules superpose with a r.m.s. deviation of 0.55Å over 884 Ca
atoms, with key AMP-interacting residues having the same
conformation. In contrast, the C2-bound molecule has an r.m.s.
deviation of 0.75Å (over 864 Ca atoms) when superimposed with
4CFE8. The largest structural difference between the C2 and
AMP-bound heterotrimer is in the b-CBM and the N-lobe of the
kinase domain, where a shift of up to 4.0 Å occurs (Fig. 3a). This
shift reﬂects the formation of a canonical kinase salt bridge,
formed between conserved residues a-Lys45 and a-Glu64, in the
C2-bound heterotrimer. This important interaction is regarded as
an active kinase conformation signature20 and is conspicuously
absent in previous a2b1g1 structures8. The C2-bound g1-subunit
conformation closely mimics that of the AMP-bound complex.
Despite the considerable chemical differences and different
binding orientations between C2 and AMP the side chains of
the g1-subunit residues are remarkably similar in conformation,
with the notable exceptions being g-Arg70 and g-His298
(Supplementary Fig. 4a,b). A region that does distinguish
between the two heterotrimers is the nucleotide sensing
a-subunit RIM2 motif1,6,8. Strong electron density was observed
for the a-RIM2 in the AMP-bound heterotrimer, but only very
weak electron density was observed for a-RIM2 in the
corresponding C2-bound heterotrimer and could therefore not
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Figure 2 | C2/A769662 synergistic activation of AMPK. Wild-type AMPK a1 and a2 were pre-treated with (a) l-phosphatase or (b) CaMKK2, and
assayed in the absence/presence of AMP (100mM) and C2 (0.1 mM), either individually or in combination with A769662 (20mM). Results from triplicate
experiments are presented as mean speciﬁc activity (nmolmin 1 mg 1±s.e.m.), with statistical tests conducted using one-way ANOVA Sidak’s multiple
comparisons test. Symbols y, w and #; Po0.01 indicate signiﬁcant increase in activity compared with A769662, C2 and AMP controls, respectively, while
NS indicates that there was no signiﬁcant difference between the co-incubated samples and their individual control samples.
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be included in this model (Supplementary Fig. 3b). This is a C2
speciﬁc effect as the previously published AMPK structure 4CFE
(crystallized in the same space group (P21) and solved to an
equivalent resolution of 3.02Å) revealed strong electron density
for both AMP-bound heterotrimers in the asymmetric unit8.
Importantly, these data are consistent with the a2-subunit RIM2
being incompletely engaged with the g-subunit when C2 is
bound.
The two C2 molecules occupy the interface between the
CBS-binding sites 1, 3 and 4, with the phosphate group of C2
occupying a similar position to that of AMP-bound phosphate
group in sites 1 and 4 (Fig. 3b). For this reason we have named
speciﬁc C2-binding sites g-pSite-1 and g-pSite-4, referring to the
equivalent AMP phosphate group position (Fig. 3b,c).
In both sites the C2 molecule makes six protein-mediated
hydrogen bond contacts, while C2 in g-pSite-4 makes an
additional p-stacking interaction with g-His298 (Fig. 3c). All of
the residues that contact C2 are shared with AMP, yet the binding
constant for C2 is 4100-fold higher than that for AMP15,16. The
basis of C2’s increased afﬁnity is not obvious to us.
Mutational analysis of the C2-binding site. To validate the
C2-binding sites, we expressed three AMPK g1 mutants (T89E,
H151E and H298E) in COS7 mammalian cells and measured
their sensitivity to C2 or AMP. We initially found that all the g1
mutants displayed increased but variable Thr172 phosphorylation
and basal activities compared with the wild-type (WT)
Table 1 | Table summarizing basal activity of AMPK a1 and a2 and their fold activation to control, calculated from data in Fig. 2.
Kinase Treatment Basal activity (nmolmin 1mg 1) (±s.e.m.) Fold activation to control (±s.e.m.)
AMP C2 A769662 AMP/A769662 C2/A769662
a1 l-Phosphatase 0.6±0.2 7.7±0.3 8.8±0.3 91.8±5.9 1100±77 1040±43
CaMKK2 699.8±26.1 1.7±0.1 2.5±0.1 1.5±0.1 1.0±0.1 1.1±0.1
a2 l-Phosphatase 1.2±0.4 3.9±0.5 2.1±0.3 1.1±0.1 6.1±0.1 1.2±0.2
CaMKK2 697.6±36.6 1.8±0.1 1.9±0.1 7.7±0.3 5.4±0.5 6.8±0.3
Table 2 | Data collection and reﬁnement statistics.
Data collection 4ZHX 5EZV
Space group P21 P21
Cell dimensions
a, b, c (Å) 76 134.2 141.5 75.6 134.1 141.3
a, b, g () 90 93.0 90 90 93.2 90
Resolution (Å) 48.66–2.99 (3.07-2.99)* 49.3–2.99 (3.08-2.99)
Rpim (%) 0.071 (0.48) 0.053 (0.31)
Rmerge (%) 0.096 (0.61) 0.081 (0.47)
oI/s(I)4 8.1 (2.2) 10.1 (2.6)
CC1/2 0.98 (0.56) 0.99 (0.77)
Completeness 98.8 (99.4) 99.4 (98)
Redundancy 3.2 (3.2) 3.2 (3.2)
Wilson B 83.8 87.4
Reﬁnement statistics
Resolution (Å) 43.78–2.99 49.3–2.99
No. of reﬂections
Total 183,106 182,062
Unique 56,598 56,584
Rwork/Rfree 22.6/24.4 22.4/24.5
No. of atoms
Protein 14,501 14,403
Ligand/ion 382 328
Water 142 104
B-factors
Overall 69.7 66.5
Protein 70 67.6
Ligand 56.2 62.8
Water 42.3 51.9
R.m.s. deviations
Bond lengths (Å) 0.007 0.008
Bond angles () 0.94 0.98
Molprobity
Clash score 2.55 (100th percentile) 5.74 (100th percentile)
Ramachandran
Favoured 96.30% 97.37%
Outliers 0.28% 0.05%
Protein geometry 1.38 (100th percentile) 1.43 (100th percentile)
*Highest resolution shell is shown in parenthesis. Each data set was obtained from a single crystal.
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g1-containing AMPK complexes. We therefore co-expressed the
mutants with the phospho-mimetic AMPK a1(T172D), which is
more amenable to studying the effect of these g mutations on
allosteric activation (Supplementary Fig. 2b)5,21. C2 and AMP
activated the AMPK a1(T172D) b1g1 enzyme to a similar extent
(E 8- and 10-fold, respectively; Fig. 4a). The g-T89E and
g-H298E mutants had increased basal activities (9.5±0.2 and
11.4±0.2 nmolmin 1mg 1 lysate for g-T89E and g-H298E,
respectively) in the absence of C2 and AMP compared with g1
WT (1.4±0.1 nmolmin 1mg 1 lysate), and were insensitive to
further activation by either C2 or AMP (Fig. 4a). It is possible that
substituting for a negatively charged glutamate residue at the T89
and H298 positions mimics the effect of the phosphate groups
of AMP or C2, resulting in constitutive activation. This would
also explain the increased Thr172 phosphorylation observed
with these mutants. The gH151E mutation completely abolished
AMPK activation by C2 (Fig. 4a,c), while only partially reducing
AMP-dependence and sensitivity compared to the wild-type
control (Fig. 4a,b).
C2-induced conformational rearrangements of the c-subunit.
A superposition of the two AMPK heterotrimers reveals two
major side-chain conformational changes between AMP and C2
binding. Firstly, the imidazole ring of the aforementioned
g-His298 has ﬂipped 180 and rotated at the Cb490 (B 6.0 Å)
to form a p-stacking interaction with C2 in g-pSite-4 while
simultaneously blocking site 3, mimicking ATP-bound AMPK
(PDB 4EAK)3 (Supplementary Fig. 4a). The conformational
difference of the g-His298 side chain is critical for AMP or C2
binding. Secondly, the position of C2 at g-pSite-1 causes the side-
chain guanidine group of g-Arg70 to shift approximately
4Å away from the AMP-bound conformation. In this new
conformation, g-Arg70 would clash with critical AMP-sensing
residue a-Glu368 from the aRIM2 (Supplementary Fig. 4b).
The clash may cause a-Glu368 to lose hydrogen bonds to site 3
AMP-interacting residues g-Arg70 and g-Lys170, that tether
a-Glu368 to the g-subunit1,6,8. In turn, this causes the aRIM2
disengagement. The loss of RIM2 association with the g-subunit
leads to the loss of protection from a-Thr172 dephosphorylation
and a concomitant reduction in Vmax with C2 as shown by
Hunter et al.16. In support of this proposal, previous studies have
shown that a-Glu368 mutation results in a comparable reduction
in Vmax with AMP stimulation and a-Thr172 dephosphorylation
protection6–8.
AMPK isoform speciﬁcity of C2 allosteric activation. Secondary
structure elements of aRIM2 are crucial for the isoform speciﬁcity
of C2. Structural comparison of a1 and a2 isoform aRIM2/
g-subunit interactions reveal the a-helical a1RIM2 (PDB 4CFH)1
forms a strong interaction (three hydrogen bonds and six salt-
bridges)22 with the g-subunit in a groove between g-helix a10 and
g-helix a4, formed upon AMP or C2 binding (Supplementary
Fig. 3b,c). In contrast, a2 isoforms have a loop motif (PDB 4ZHX
and 4CFE)8 that forms a single hydrogen bond and four
salt-bridges22 with the g-subunit (Supplementary Fig. 3b,c). We
propose the weaker interacting a2 isoform aRIM2 is incompletely
engaged upon C2 binding relative to the a1 isoform, resulting in
the a-isoform speciﬁcity for allosteric and synergistic activation
and protection from a-Thr172 dephosphorylation. We solved the
X-ray crystal structure of a heterotrimeric a2/a1 RIM chimaera,
a2(1-347)/a1(349-401)/a2(397-end) b1g1 (which has previously
been shown to completely restore maximal allosteric activation
and C2-mediated protection of a-Thr172 dephosphorylation16),
co-crystallized with C2 to 2.99Å (pdb: 5EZV; Table 2). Unlike the
aforementioned crystal structure (4ZHX), a2/a1 RIM swap
chimaera was crystallized in the absence of AMP, revealing two
C2-bound AMPK heterotrimers in the asymmetric unit. Both
of the C2-bound heterotrimers (5EZV) closely resembled the
S314
S316
H151
R152
T87
T89
H298
S226C2
CBM
Kinase
domain
γ-subunit
β-subunit
α-subunit
A-769662
Staurosporine
C2 (×2)
a
R299
γ-pSite-1
γ-pSite-4
Site 4
Site 3
Site 1
C2
b
c
AMP (×2)
~ 4 Å
Figure 3 | C2 binds the c-subunit of AMPK. (a) Cartoon representation of the AMPK heterotrimer (a2b1g1) bound to C2 (yellow sticks) in the
g-subunit (magenta), Staurosporine bound to the a-subunit (green) and A769662 bound at the ADaM binding site at the interface of the a-kinase domain
and the CBM of the b-subunit (cyan) superimposed with the AMP-bound heterotrimer (white). Arrow shows the approximate distance between equivalent
bCBM residues in the C2-bound and AMP-bound heterotrimers. (b) The position of C2 with respect to CBS sites, with AMP superimposed (from PDB
4CFE). (c) AMPK interactions (black dashed lines and blue parallel lines for p stacking) with C2 (yellow sticks). Key residues (labelled) are modelled as
sticks. Note that g-Arg299 was modeled in two discrete conformations.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10912 ARTICLE
NATURE COMMUNICATIONS | 7:10912 | DOI: 10.1038/ncomms10912 | www.nature.com/naturecommunications 5
previous C2-bound heterotrimer (molecule 1 4ZHX), with an
r.m.s deviation of 0.520 over 869 Ca atoms (molecule 1 5EZV).
The C2 molecules occupy the same binding space and g-subunit
residue interactions as the AMP/C2-bound structures (4ZHX).
Importantly the structure reveals density for seven a1 RIM 2
residues (Fig. 5), including the main-chain of the nucleotide
sensing a-E364 (a2 E368), further supporting our proposal that
the a1 RIM2 interacts more strongly with the g-subunit.
Interestingly there was weak density for the carboxyl group of
the E364 side-chain, possibly indicating a transient interaction
with the g-subunit residue R70.
Discussion
In this study we showed that two topographically disparate drug
sites on AMPK, one located at the classic a-kinase domain/
b-CBM interface (ADaM site) and the other located within the
solvent-accessible core of the g-subunit (g-pSite-1/g-pSite-4), can
be exploited to achieve synergistic activation of unphosphorylated
a1-AMPK independent of AMP and upstream phosphorylation
events. This provides a major advance to previous demonstra-
tions of AMPK synergistic activation that have been dependent
on AMP. Importantly, identiﬁcation of C2-binding sites on the
g-subunit represents an entirely unexplored dimension for future
rational drug design.
Methods
Reagents. Antibodies for pan AMPK a (#2793), FLAG (#2368) and HA (#2367);
phosphospeciﬁc antibodies for a-pThr172 (#2535) and b-pSer108 (#4181), and
l-phosphatase (#P0753) were from Cell Signaling Technology. b1 antibody
(#ab58175) and A769662 (#ab120335) were from Abcam. Anti-rabbit and anti-
mouse IgG secondary antibodies ﬂuorescently labelled with IR680 or IR800 dye,
respectively, were from LI-COR Biosciences. Glutathione Sepharose 4B was from
GE Life Sciences. FLAG peptide (DYKDDDK) was provided by GL Biochem
(Shanghai), puriﬁed by reversed-phase chromatography and stored as lyophilized
powder. All other reagents were purchased from Sigma.
Constructs for crystallization. All mutants were generated using QuikChange
Site-Directed Mutagenesis Kits (Stratagene), and constructs were sequence veriﬁed.
Escherichia coli-expressed AMPK preparations were mass veriﬁed by time-of-ﬂight
(TOF) mass spectrometry. Heterotrimeric human AMPK His6-a2b1g1 was
expressed in E. coli strain Rosetta (DE3) using the pETDuetTM-1 expression system
(Novagen) as previously described13. Brieﬂy, cDNAs for a2 and g1were
sequentially inserted into pETDuetTM-1 multiple cloning sites (MCS) 1 (BamH1/
Not1) and 2 (MfeI/XhoI), respectively, resulting in incorporation of an N-terminal
hexahistidine tag onto a2. cDNA for b1 was inserted into pRSFDuetTM-1 MCS1
(NcoI/ BamHI). Heterotrimeric human AMPK a2/a1 RIM chimaera (a2(1-347)/
a1(349-401)/a2(397-end) b1g1)16 was expressed in E. coli strain Rosetta (DE3)
using the pETDuetTM-1 and pCOLADuetTM (Novagen). cDNAs for a2/1 chimaera
and g1were sequentially inserted into pETDUETTM-1 multiple cloning sites (MCS)
1 (BamHI/Not1) and 2 (MfeI/XhoI), respectively, resulting in incorporation of an
N-terminal hexahistidine tag onto a2/1 chimaera. cDNA for b1 was inserted into
pCOLADuetTM-1 MCS1 (NcoI/ BamHI).
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Figure 4 | Effect of AMPK c-subunit mutations on C2 activity. AMPK
a1b1g1 phospho-mimetic T172D and their respective g mutants T89E,
H151E, and H298E were expressed as FLAG-a fusion proteins in COS7
mammalian cells. (a) Activities of AMPK mutants were tested in the
absence or presence of C2 (5 mM) or AMP (100mM). Results from four
independent experiments are presented as speciﬁc activity
(nmolmin 1 mg 1 lysate±s.e.m.), with statistical tests conducted using
one-way ANOVA. *Po0.05 indicates signiﬁcant increase in activity
compared with untreated control. (b) AMP dose–response of AMPK
a1-T172D g1 wild-type and g1-H151E mutants (0–500mM). The data
was plotted as AMPK activity (nmolmin 1 mg 1 lysate±s.e.m.) versus
[AMP] (mM) from four independent experiments. (c) C2 dose–response
of AMPK a1-T172D g1 wild-type and g1-H151E mutants (0–5mM).
Curve was plotted as AMPK activity (nmolmin 1 mg 1 lysate±s.e.m.)
versus [C2] (mM) from four independent experiments. The values for
EC50 and fold stimulation were calculated based on ﬁtting the data to the
equation: Activity¼ Basalþ (((Fold stimulationBasal) Basal [C2])/
((EC50)þ [C2])).
E364
C2
RIM2
γ-subunit
Figure 5 | Omit map of the a1RIM2 with C2 bound in the c-subunit. Stereo 2Fo–Fc omit map of the a1RIM2 (yellow) from the heterotrimeric human AMPK
RIM swap chimaera (a2 1-347/a1 349-401/a2 397-end b1g1) bound to C2, contoured at 1s. Continuous density (white mesh) can be seen for seven
residues of the a1RIM2, including E364 (a2 E368). Weak density for the side-chain carboxyl of E364 suggests some interaction with C2 (orange sticks)
bound g-subunit (blue).
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Protein expression and puriﬁcation for crystallization. Expression cultures
were grown in Luria-Bertani broth and induced at 16 C with 0.25mM isopropyl
b-D-1-thiogalactopyranoside, before overnight incubation. Cells were lysed using a
precooled EmulsiFlex-C5 homogenizer (Avestin) and AMPK puriﬁed using Nickel
Sepharose and size exclusion chromatography in 50mM Tris–HCl, pH 8.0,
150mM NaCl, 2mM Tris(2-carboxyethyl)phosphine buffer. AMPK was
phosphorylated by incubation with CaMKK2 (expressed in Sf21 cells as a
C-terminal FLAG fusion and puriﬁed on FLAG monoclonal antibody-coupled
afﬁnity resin2) in the presence of 2.5mM MgCl2, 0.5mM ATP and 0.5mM
AMP (1 h, 22 C). Protein was re-puriﬁed using size exclusion chromatography,
concentrated to B10mgml 1 and ﬂash frozen in liquid nitrogen before storage
at  80 C (storage buffer: 50mM Tris–HCl, pH 8.0, 150mM NaCl, 2mM
Tris(2-carboxyethyl)phosphine).
Crystallization. Full-length myristoylated and phosphorylated a2b1g1
(4mgml 1) was mixed with a twofold molar excess of C2, AMP and S108tide
(synthetic peptide: b1(102-117) R115-117, NH2-KLPLTRSHNNFVARRR-COOH)
and a 1:1 molar ratio of Staurosporine and A769662, while full-length
phosphorylated RIM swap chimaera (a2 1-347/a1 349-401/a2 397-end b1g1)16
(4mgml 1) was mixed with a sixfold molar excess of C2, twofold molar excess of
S108tide and a 1:1 molar ratio of Staurosporine and A769662. Crystals from both
protein preparations were grown following the previously described method8.
Brieﬂy, protein was mixed equally at room temperature with a reservoir solution
containing 8% PEG 3350, 0.1 M MgCl2, 1.0% glucose, 0.001% cocamidopropyl
betaine and 0.1M imidazole (pH 6.2). Protein crystals were incubated with
reservoir solution containing an additional 5% glycerol, 5% PEG 400, 5% MPD, 5%
sucrose, 5% sorbitol and 5% ethylene glycol forB2min before ﬂash-cooling in
liquid nitrogen. Data were collected at the Australian Synchrotron MX2 beamline,
Melbourne, Australia. Data were processed and integrated using XDS23 and scaled
using AIMLESS from the CCP4 suite24. The structure was solved by molecular
replacement using Phaser from the CCP4 suite25 and 4CFE8 as the search model.
Iterative rounds of model building and reﬁnement were performed using Coot26
and Buster (https://www.globalphasing.com/buster/)27 respectively. C2 molecular
coordinates and restraints were generated using the PRODRG web-server28. Omit
maps were calculated using Sfcheck in the CCP4 suite29. Structure validation and
protein–C2 interactions was performed using Molprobity30, ﬁgures were created
using Pymol (https://www.pymol.org/). Data collection and reﬁnement statistics
are listed in Table 2.
Protein expression and puriﬁcation for AMPK enzyme assays. All mutants
were generated using QuikChange Site-Directed Mutagenesis Kits (Stratagene), and
constructs were sequence veriﬁed. Heterotrimeric AMPK was expressed in COS7
mammalian cells by transient transfection, using FuGENE HD (Promega)
transfection reagent according to manufacturer’s protocol. Transfected constructs
included N-terminal GST-a1 and a2 fusions2 (pDEST27 expression vector),
C-terminal FLAG- a1 and a2 fusions (cloned into pcDNA3.1 expression vector
using XhoI/EcoRI (a1) or XhoI/HindIII (a2) restriction sites, C-terminal myc-b1
and b2 fusions31 (pcDNA3.1 expression vector) and N-terminal HA-g1, g2 and g3
fusions32 (pMT2 expression vector). To assess C2 g isoform selectivity and C2
kinetics (Fig. 1): GST-a1b1/2g1/2/3 AMPK complexes were isolated from
transfected lysates by immobilization on Glutathione Sepharose 4B (GE Life
Sciences) prior to SAMS activity assay2. To assess C2/A769662 synergy (Fig. 2):
GST-a1b1g1 and GST-a2b1g1 AMPK complexes were immobilized on
Glutathione Sepharose 4B and incubated with either l-phosphatase (50mM
Tris–HCl pH 7.4, 150mM NaCl, 10% glycerol, 0.01% Tween-20 (buffer A)
supplemented with 2mM MnCl2) or CaMKK2 (buffer A supplemented with 2mM
MgCl2, 200mM ATP) (1 h, 22 C) prior to extensive washes with buffer A and
elution in buffer A supplemented with 20mM glutathione. The levels of a-pThr172
and b-pSer108 of treated AMPK complexes were assessed by immunoblot as
described previously32 (Supplementary Fig. 2a). Brieﬂy, membranes were
simultaneously probed overnight at 4 C with a phosphospeciﬁc primary antibody
for a-pThr172 (1:2,000 dilution in phosphate buffered saline with 0.1% Tween-20
(v/v) (PBS-T)) or b-pSer108 (1:2,000 dilution in PBS-T) labelled with the
ﬂuorescent dye IR680 (LI-COR Biosciences) and probed for 1 h at room temp with
pan a primary antibodies (1:1,000 dilution in PBS-T) or b1 primary antibodies
(1:1,000 dilution in PBS-T) ﬂuorescently labelled with IR800. Immunoreactive
bands were visualized on an Odyssey membrane imaging system (LI-COR
Biosciences) and densitometry analyses performed using integrated software.
To evaluate the impact of g-mutation on C2/AMP activity (Fig. 4): FLAG-
a1(T172D)b1g1 (wild-type and indicated mutants) AMPK complexes were
immobilized on anti-FLAG M2 afﬁnity Agarose gel (Supplementary Fig. 2b) before
SAMS activity assay. The expression levels of the g-mutants were assessed by
immunoblot. Membrane was probed overnight at 4 C with a FLAG primary
antibody (1:2,000 dilution in PBS-T) labelled with the ﬂuorescent dye IR680
(LI-COR Biosciences) and probed for 1 h at room temp with HA primary
antibodies (1:1,000 dilution in PBS-T) ﬂuorescently labelled with IR800 and
analysed as above.
AMPK activity assay. AMPK activity assay was conducted as described
previously13. Brieﬂy, AMPK complexes were puriﬁed as above and washed three
times with a 40:1 v/v ratio of assay buffer/resin (assay buffer: 50mM Hepes pH 7.4,
1mM DTT and 0.02% Brij-35). Reaction mixtures (25 ml) containing 100 mM
SAMS synthetic peptide (sequence: NH2-HMRSAMSGLHLVKRR-COOH), 5mM
MgCl2, 200 mM [g-32P]-ATP were incubated AMPK for 10min at 30 C in the
absence or presence of various C2 concentrations. AMP (100 mM) and/or
A769662 (20 mM) were included as appropriate positive controls. After 10min,
phosphotransferase activity was quenched by spotting onto P81 ion-exchange
chromatography paper (Whatman, GE Healthcare, Parramatta, NSW) followed by
repeated washes in 1% H3PO4 (ref. 33). The level of 32P-transfer to the SAMS
peptide was determined by liquid scintillation counting (Perkin Elmer, Melbourne,
VIC). Statistical tests were conducted using analysis of variance (ANOVA).
The values for EC50 and fold stimulation were calculated based on the equation:
Activity¼Basalþ (((Fold stimulation x Basal)Basal [C2])/((EC50)þ [C2])).
Curve ﬁtting was performed using KaleidaGraph software.
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